Trial Profile
A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Efficacy, and Immunogenicity of Daily Subcutaneous Administration of 5 mug/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2021
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary)
- Indications Neutropenia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Teva Branded Pharmaceutical Products R&D; Teva Pharmaceutical Industries
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 01 Sep 2017 Status changed from active, no longer recruiting to completed.
- 15 Jun 2017 This trial has been completed in Bulgaria (end date: 3 Apr 2017) and Croatia (end date: 3 Apr 2017).